Posted: 06 Oct 2016 03:14 AM PDT By Kurt R. Karst – A mere 1 year and 8 months after FDA’s February 6, 2015 publication of a Proposed Rule to implement certain provisions of the December 8, 2003 Medicare Modernization Act (“MMA”), Pub. L. No. 108-173, 117 Stat. 2066, and 12 years and about 10 months after the MMA’s enactment, we finally have new Hatch-Waxman regulations. On October 6, 2016, FDA published in the Federal Register a Final Rule, titled “Abbreviated New Drug Applications and 505(b)(2) Applications,” that will forever alter the Hatch-Waxman landscape, and that will likely fuel controversies and provide fodder for litigation for years to come. The Final Rule is the latest – and most significant – in a series of actions intended by FDA to preserve the balance struck with the September 24, 1984 enactment of the Hatch-Waxman Amendments between benefits from the availability of low-cost and high quality generic drugs and the need to reward those manufacturers who bring innovative (i.e., brand-name) drug products to market. While the focus of the Final Rule is only about 10 pages of MMA statutory text, the document spans 79 triple-column pages in the Federal Register, including about 22 pages of regulations that will be codified in the Code of Federal Regulations as of December 5, 2016. Several proposals FDA made in February 2015 (see our previous post here) are retained in the Final Rule, while a few have been dropped (either because of court decisions, or because FDA decided to move in a different direction). Perhaps most significant is FDA’s decision to drop (at least for now) a proposal to defer to a 505(b)(2) or ANDA applicant’s interpretation of the scope of a patent that it does not own (and, in particular, for a method-of-use patent that is identified in the Orange Book with a patent use code and narrative). Instead, FDA will institute a patent listing dispute mechanism whereby the “NDA holder must provide a narrative description (no more than 250 words) of the NDA holder’s interpretation of the scope of the patent that explains why the existing or amended ‘use code’ describes only the specific approved method of use claimed by the patent for which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product.” As you can imagine, we’re still poring over the Final Rule. We’ll probably put together a Summary and Analysis. But for now, below are some highlights (courtesy of FDA) of the changes compared to the Proposed Rule (including references to the relevant section in the Final Rule). Also, we’ve put together a 100-page Regulation-by- Final Rule Description of Change From Proposed Rule21 C.F.R. § 314.3Definitions (§ 314.3(b))
Patent claiming drug substance, drug product or method of use (§ 314.50(f)(1)(i)(C))
Method-of-use patent (§ 314.50(i)(l)(iii)(A))
Untimely filing of patent information (§ 314.50(i)(4))
Sending the notice of paragraph IV certification (§ 314.52(b))
Content of a notice of paragraph IV certification (§ 314.32(c))
Amendment or supplement to a 505(b)(2) application (§ 314.52(d))
General requirements and Reporting Requirements (§ 314.53(b)(1) and (c)(2))
Other Reporting Requirements (§ 314.53(r)(2))
Supplements (§ 314.53(d)(2))
Where to send submissions of Forms FDA 3542a and 3542 (§ 314.53(d)(4)
Submission date of patent information (§ 314.53(d)(5))
Requests by persons other than the NDA holder (§ 314.53(f)(1))
Procedure for submission of a 505(b)(2) application requiring investigations for approval of a new indication for, or other change from, a listed drug (§ 314.54(a)(l))
Patent certification requirements (§ 314.60(f))
Patent certification requirements (§ 314.70(i))
Waivers (§ 314.90)
Petition to request a change from a listed drug (§ 314.93)
Method-of-use patent (§ 314.94(a)(12)(iii)(A))
Untimely filing of patent information (§ 314.94(a)(12)(vi))
Sending the notice of paragraph IV certification (§ 314.95(b))
Patent certification requirements (§ 314.95(d))
Patent certification requirements (§ 314.97(c))
Other responsibilities of an applicant of an ANDA (§ 314.99)
Receiving an ANDA (§ 314.101(b))
NDA or ANDA deficiencies (§ 314.101(d))
Approval of an NDA and an ANDA (§ 314.105)
Disposition of patent litigation (§ 314.107(b)(3))
Notification of court actions or written consent to approval (§ 314.107(e))
New drug product exclusivity(§ 314.108)
Refusal to approve an NDA (§ 314.125)
Refusal to approve an ANDA (§ 314.127)
Definitions (§ 320.1)
Basis for measuring in vivo bioavailability or demonstrating bioequivalence (§ 320.23)
|
jueves, 6 de octubre de 2016
FDA Law Blog: FDA Issues Final Hatch-Waxman Regulations to Implement Some of the Provisions of the 2003 Medicare Modernization Act
FDA Law Blog: FDA Issues Final Hatch-Waxman Regulations to Implement Some of the Provisions of the 2003 Medicare Modernization Act
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario